VTV ETF Rises 0.9%, Outperforms Underlying Index
Dow Jones2026/10/29 20:37This article was automatically generated using Dow Jones technology.
Shares of Vanguard Morningstar Value ETF rose 0.9% to $228.88 Thursday on what proved to be an overall unfavorable trading session for the U.S. stock market, with the S&P 500 Index falling 0.3% to 7,720.39.
This was the fund's second consecutive day of gains. The fund's underlying index, the CRSP US Large Cap Index, fell 0.4%.
Trading volume was 2,494,644, compared to the 65-day average trading volume of 2,659,194.
As of October 28, the fund's net asset value totaled $226.83 per share.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
October 29, 2026 16:37 ET (20:37 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Asia-Pacific stock markets follow the overnight rally in US tech stocks, with South Korea's KOSPI up 5% at the open, SK Hynix surging more than 7%, and Nikkei 225 rising over 2%.
This round of rebound occurred after the market experienced severe turbulence. Last week, concerns over the potential for stricter regulation of the artificial intelligence industry, due to the US Congressional election results, triggered a large-scale sell-off in chip stocks. Several market participants believe that this rebound indicates investors have not abandoned the AI trading narrative, and last week’s sell-off was more about position adjustments rather than a trend reversal.
Barrick’s Marquee gold project faces hazy study timing
Japanese and South Korean stock markets open

Marvell Technology (MRVL.US) $115 billion "merger of the century" faces lukewarm reception! Stock has dropped over 40%, experts estimate only a 50% chance of completion
Marvell plans to acquire Lamington for 115 billions USD to strengthen its position in AI, but the probability of completion is only 50%. The two stocks have dropped by nearly 40% and about 35% respectively, with Chinese regulatory approval being the biggest uncertainty.